Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis

对于大多数转移性结直肠癌（mCRC）患者而言，FOLFOXIRI单药治疗或联合靶向治疗作为一线治疗方案是否合理？系统评价和网络荟萃分析